The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus

The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus

Prevention and choice of therapeutic strategies in patient,s with type 2 diabetes (T2D) and heart failure (HF) is an urgent problem. This review presents a modern concept for HF development from early stages of T2D. Glucose-lowering and cardiac medications for the prevention and treatment...

Full description

Bibliographic Details
Main Authors:	Zh. D. Kobalava, V. V. Medovchshikov, N. B. Yeshniyazov, E. R. Khasanova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2019-11-01
Series:	Российский кардиологический журнал
Subjects:	diabetes heart failure subclinical myocardial dysfunction diabetic cardiomyopathy diabetic nephropathy preserved ejection fraction pathophysiology sglt2 inhibitors
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3581

Similar Items

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
by: Zh. D. Kobalava, et al.
Published: (2020-06-01)

Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options
by: A. A. Borisov, et al.
Published: (2021-07-01)

Effect of empagliflozin on the left ventricular diastolic function in patients with type 2 diabetes mellitus and concomitant heart failure with preserved ejection fraction
by: A.S. Herashchenko, et al.
Published: (2023-09-01)

Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction
by: Ke Shi, et al.
Published: (2021-09-01)

Diabetes Mellitus and Heart Failure
by: Wun-Zhih Siao, et al.
Published: (2022-10-01)

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
by: Chao Ma, et al.

Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
by: Alfredo Caturano, et al.
Published: (2022-05-01)

Impact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation
by: N.M. Kulaiets, et al.
Published: (2023-12-01)

Subclinical right ventricular dysfunction in patients with asymptomatic type 2 diabetes mellitus: A cross-sectional study
by: Prabhat Rijal, et al.
Published: (2023-11-01)

Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
by: Ahmed Elsanhoury, et al.
Published: (2021-09-01)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
by: Giuseppe Palmiero, et al.
Published: (2021-05-01)

Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications
by: Xinqian Geng, et al.
Published: (2022-05-01)

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes
by: D. A. Lebedev, et al.
Published: (2020-11-01)

Editorial: Molecular Pathophysiology of Diabetes-Related Organ Injury
by: Tingting Zhao, et al.
Published: (2022-03-01)

Thyroid Dysfunction among Patients with Diabetes Mellitus in Kathmandu
by: Khema Raj Bhusal, et al.
Published: (2018-12-01)

SGLT2 inhibitors in heart failure with reduced ejection fraction
by: Uday Sankar Das, et al.
Published: (2021-10-01)

Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update
by: Ioanna Koniari, et al.
Published: (2022-08-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Cardiovascular risk in type 1 diabetes mellitus
by: Ines Ben Hadj Slama Slim
Published: (2013-01-01)

The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
by: Teresa Salvatore, et al.
Published: (2021-06-01)

Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication
by: Michael Lichtenauer, et al.
Published: (2021-05-01)

Diabetes mellitus: From molecular mechanism to pathophysiology and pharmacology
by: Oluwafemi Adeleke Ojo, et al.
Published: (2023-09-01)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
by: Panagiotis Theofilis, et al.
Published: (2023-02-01)

Cardiac Dysfunction in Early Stages of Diabetic Kidney Disease- Fact or Fiction: A Case-control Study
by: Richard Bruno Michael, et al.
Published: (2022-12-01)

Pharmacological modulation of prostaglandin E2 (PGE2) EP receptors improves cardiomyocyte function under hyperglycemic conditions
by: Karin J. Bosma, et al.
Published: (2022-04-01)

Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus
by: Raluca D. Ianoș, et al.
Published: (2021-08-01)

Can We Prevent Mitochondrial Dysfunction and Diabetic Cardiomyopathy in Type 1 Diabetes Mellitus? Pathophysiology and Treatment Options
by: Aleksandra Cieluch, et al.
Published: (2020-04-01)

Mechanisms of Diabetic Nephropathy Not Mediated by Hyperglycemia
by: Davide Viggiano
Published: (2023-10-01)

Association between subclinical hypothyroidism and diabetic nephropathy in type 2 diabetes
by: Ayman Abd-Elrahman Mohamed Nsr-Allah, et al.
Published: (2018-01-01)

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
by: Bin Feng, et al.
Published: (2023-06-01)

Predictors of in-hospital mortality in diabetic patients with non-ST-elevation myocardial infarction
by: Seyyed Mojtaba Ghorashi, et al.
Published: (2022-03-01)

Diabetes Mellitus and Heart Failure
by: Filippos Triposkiadis, et al.
Published: (2021-08-01)

Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
by: Laurent Fauchier, et al.
Published: (2023-02-01)

Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions
by: Alfredo Caturano, et al.
Published: (2024-02-01)

Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus
by: Louis Potier, et al.
Published: (2018-01-01)

Therapeutic Advances in Diabetic Nephropathy
by: Hanny Sawaf, et al.
Published: (2022-01-01)

Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report
by: Felice Nappi, et al.
Published: (2019-08-01)

Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
by: Chan-Young Jung, et al.
Published: (2022-03-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
by: M. A. Manukyan, et al.
Published: (2021-11-01)

Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study
by: Xi Liu, et al.
Published: (2018-10-01)